Despite the clinical benefit of anti-PD-1 therapy across a wide range of malignancies (Ribas and Wolchok, 2018), only a small subset of GC patients exhibited durable response (Boku et al., 2021; Janjigian et al., 2021). This evidence concerns the gene PDCD1 and gastric cancer.